Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.

Eur J Pharmacol. 2012 Jun 5;684(1-3):64-70.

2.

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.

J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30.

3.

Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.

J Neurosci Methods. 2011 Jul 15;199(1):62-8. doi: 10.1016/j.jneumeth.2011.04.036. Epub 2011 May 6.

4.

Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.

Tumati S, Roeske WR, Vanderah TW, Varga EV.

Eur J Pharmacol. 2010 Dec 1;648(1-3):95-101. doi: 10.1016/j.ejphar.2010.08.042. Epub 2010 Sep 15.

5.

Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.

Br J Pharmacol. 2010 Sep;161(1):51-64. doi: 10.1111/j.1476-5381.2010.00869.x.

6.

Functional selectivity in cannabinoid signaling.

Varga EV, Georgieva T, Tumati S, Alves I, Salamon Z, Tollin G, Yamamura HI, Roeske WR.

Curr Mol Pharmacol. 2008 Nov;1(3):273-84. Review.

PMID:
20021440
7.

Sustained morphine treatment augments capsaicin-evoked calcitonin gene-related peptide release from primary sensory neurons in a protein kinase A- and Raf-1-dependent manner.

Tumati S, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.

J Pharmacol Exp Ther. 2009 Sep;330(3):810-7. doi: 10.1124/jpet.109.151704. Epub 2009 Jun 2.

8.

Sustained cannabinoid agonist treatment augments CGRP release in a PKA-dependent manner.

Tumati S, Yamamura HI, St John PA, Vanderah TW, Roeske WR, Varga EV.

Neuroreport. 2009 May 27;20(8):815-9. doi: 10.1097/WNR.0b013e32832be50b.

PMID:
19387418
9.

Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.

Tumati S, Milnes TL, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.

Eur J Pharmacol. 2008 Dec 28;601(1-3):207-8. doi: 10.1016/j.ejphar.2008.10.033. Epub 2008 Oct 21.

10.

Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.

Yue X, Tumati S, Navratilova E, Strop D, St John PA, Vanderah TW, Roeske WR, Yamamura HI, Varga EV.

Eur J Pharmacol. 2008 Apr 28;584(2-3):272-7. doi: 10.1016/j.ejphar.2008.02.013. Epub 2008 Feb 14.

11.

Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Georgieva T, Devanathan S, Stropova D, Park CK, Salamon Z, Tollin G, Hruby VJ, Roeske WR, Yamamura HI, Varga E.

Eur J Pharmacol. 2008 Feb 26;581(1-2):19-29. Epub 2007 Nov 28.

12.

Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell.

Huang MH, Wang HQ, Roeske WR, Birnbaum Y, Wu Y, Yang NP, Lin Y, Ye Y, McAdoo DJ, Hughes MG, Lick SD, Boor PJ, Lui CY, Uretsky BF.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H376-84. Epub 2007 Mar 16.

13.

Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action.

Navratilova E, Waite S, Stropova D, Eaton MC, Alves ID, Hruby VJ, Roeske WR, Yamamura HI, Varga EV.

Mol Pharmacol. 2007 May;71(5):1416-26. Epub 2007 Feb 22.

PMID:
17322005
14.

Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074.

Yue X, Varga EV, Stropova D, Vanderah TW, Yamamura HI, Roeske WR.

Eur J Pharmacol. 2006 Jul 1;540(1-3):57-9. Epub 2006 May 3.

PMID:
16750187
15.

Morphine promotes phosphorylation of the human delta-opioid receptor at serine 363.

Navratilova E, Eaton MC, Stropova D, Varga EV, Vanderah TW, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Sep 20;519(3):212-4.

PMID:
16135360
16.

Antinociception depends on the presence of G protein gamma2-subunits in brain.

Varga EV, Hosohata K, Borys D, Navratilova E, Nylen A, Vanderah TW, Porreca F, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Jan 31;508(1-3):93-8. Epub 2005 Jan 12.

PMID:
15680258
17.

Agonist-specific regulation of the delta-opioid receptor.

Varga EV, Navratilova E, Stropova D, Jambrosic J, Roeske WR, Yamamura HI.

Life Sci. 2004 Dec 24;76(6):599-612. Review.

PMID:
15567186
18.

Neuroendocrine properties of intrinsic cardiac adrenergic cells in fetal rat heart.

Huang MH, Bahl JJ, Wu Y, Hu F, Larson DF, Roeske WR, Ewy GA.

Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H497-503. Epub 2004 Sep 30.

19.

Mutation S363A in the human delta-opioid receptor selectively reduces down-regulation by a peptide agonist.

Navratilova E, Varga EV, Stropova D, Jambrosic JC, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2004 Feb 6;485(1-3):341-3.

PMID:
14757159
20.

Postural position and neurocardiogenic syncope in late pregnancy.

Huang MH, Roeske WR, Hu H, Indik JH, Marcus FI.

Am J Cardiol. 2003 Nov 15;92(10):1252-3.

PMID:
14609615
21.

Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment.

Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, Roeske WR.

Life Sci. 2003 Dec 5;74(2-3):299-311. Review.

PMID:
14607258
22.

Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment.

Varga EV, Rubenzik MK, Stropova D, Sugiyama M, Grife V, Hruby VJ, Rice KC, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2003 Jul;306(1):109-15. Epub 2003 Mar 26.

PMID:
12660310
23.

(2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.

Hosohata K, Varga EV, Alfaro-Lopez J, Tang X, Vanderah TW, Porreca F, Hruby VJ, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2003 Feb;304(2):683-8.

PMID:
12538822
24.

Agonist-specific down-regulation of the human delta-opioid receptor.

Okura T, Varga EV, Hosohata Y, Navratilova E, Cowell SM, Rice K, Nagase H, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2003 Jan 10;459(1):9-16.

PMID:
12505529
25.

Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation.

Varga EV, Rubenzik M, Grife V, Sugiyama M, Stropova D, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2002 Sep 6;451(1):101-2.

PMID:
12223234
27.

Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation.

Hosohata Y, Varga EV, Stropova D, Li X, Knapp RJ, Hruby VJ, Rice KC, Nagase H, Roeske WR, Yamamura HI.

Life Sci. 2001 Apr 6;68(19-20):2233-42.

PMID:
11358332
28.

The role of the G protein gamma(2) subunit in opioid antinociception in mice.

Hosohata K, Logan JK, Varga E, Burkey TH, Vanderah TW, Porreca F, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2000 Mar 31;392(3):R9-R11.

PMID:
10762674
29.

delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice.

Hosohata Y, Vanderah TW, Burkey TH, Ossipov MH, Kovelowski CJ, Sora I, Uhl GR, Zhang X, Rice KC, Roeske WR, Hruby VJ, Yamamura HI, Lai J, Porreca F.

Eur J Pharmacol. 2000 Feb 4;388(3):241-8.

PMID:
10675732
30.

Differential down-regulation of the human delta-opioid receptor by SNC80 and [D-Pen(2),D-Pen(5)]enkephalin.

Okura T, Cowell SM, Varga E, Burkey TH, Roeske WR, Hruby VJ, Yamamura HI.

Eur J Pharmacol. 2000 Jan 10;387(2):R11-3.

PMID:
10650167
31.

Coupling of human delta-opioid receptor to retinal rod transducin in Chinese hamster ovary cells.

Varga EV, Stropova D, Kim T, Wang M, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2000 Jan;292(1):209-14.

PMID:
10604950
32.

(2S,3R)TMT-L-Tic-OH is a potent inverse agonist at the human delta-opioid receptor.

Hosohata K, Burkey TH, Alfaro-Lopez J, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1999 Sep 3;380(1):R9-10.

PMID:
10513562
33.

The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy.

Quock RM, Burkey TH, Varga E, Hosohata Y, Hosohata K, Cowell SM, Slate CA, Ehlert FJ, Roeske WR, Yamamura HI.

Pharmacol Rev. 1999 Sep;51(3):503-32. Review. No abstract available.

PMID:
10471416
34.

Phosphorylation of adenylyl cyclase VI upon chronic delta-opioid receptor stimulation.

Varga EV, Stropova D, Rubenzik M, Waite S, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1999 Jan 8;364(2-3):R1-3.

PMID:
9932732
35.

Structural correlates for down-regulation of m1 and m2 muscarinic receptor subtypes.

Malatynska E, Waite S, Wei HB, Knapp RJ, Yamamura HI, Roeske WR.

Brain Res Bull. 1998 Oct;47(3):285-90.

PMID:
9865862
36.

Identification of adenylyl cyclase isoenzymes in CHO and B82 cells.

Varga EV, Stropova D, Rubenzik M, Wang M, Landsman RS, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1998 May 8;348(2-3):R1-2.

PMID:
9652350
37.

Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor.

Hosohata K, Burkey TH, Alfaro-Lopez J, Varga E, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1998 Apr 3;346(1):111-4.

PMID:
9617760
38.

The efficacy of delta-opioid receptor-selective drugs.

Burkey TH, Ehlert FJ, Hosohata Y, Quock RM, Cowell S, Hosohata K, Varga E, Stropova D, Li X, Slate C, Nagase H, Porreca F, Hruby VJ, Roeske WR, Yamamura HI.

Life Sci. 1998;62(17-18):1531-6. Review.

PMID:
9585131
39.

AM630 is an inverse agonist at the human cannabinoid CB1 receptor.

Landsman RS, Makriyannis A, Deng H, Consroe P, Roeske WR, Yamamura HI.

Life Sci. 1998;62(9):PL109-13.

PMID:
9496703
40.

Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.

Kovacs I, Yamamura HI, Waite SL, Varga EV, Roeske WR.

J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.

PMID:
9454790
41.

Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.

Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Oct 8;336(2-3):295-8.

PMID:
9384246
42.

SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.

Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Sep 3;334(1):R1-2.

PMID:
9346339
43.

Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor.

Quock RM, Hosohata Y, Knapp RJ, Burkey TH, Hosohata K, Zhang X, Rice KC, Nagase H, Hruby VJ, Porreca F, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 May 12;326(1):101-4.

PMID:
9178661
44.

delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.

Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Apr 4;323(2-3):R3-4.

PMID:
9128853
45.

AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.

Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Feb 19;321(1):R1-3.

PMID:
9083796
46.

AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain.

Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.

Life Sci. 1997;61(9):PL115-8.

PMID:
9284087
47.

The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.

Varga EV, Li X, Stropova D, Zalewska T, Landsman RS, Knapp RJ, Malatynska E, Kawai K, Mizusura A, Nagase H, Calderon SN, Rice K, Hruby VJ, Roeske WR, Yamamura HI.

Mol Pharmacol. 1996 Dec;50(6):1619-24. Erratum in: Mol Pharmacol 1997 Aug;52(2):335.

PMID:
8967985
48.

Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80.

Malatynska E, Wang Y, Knapp RJ, Waite S, Calderon S, Rice K, Hruby VJ, Yamamura HI, Roeske WR.

J Pharmacol Exp Ther. 1996 Sep;278(3):1083-9.

PMID:
8819489
49.

Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.

Knapp RJ, Santoro G, De Leon IA, Lee KB, Edsall SA, Waite S, Malatynska E, Varga E, Calderon SN, Rice KC, Rothman RB, Porreca F, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 1996 Jun;277(3):1284-91.

PMID:
8667189
50.

delta-Opioid receptor: the third extracellular loop determines naltrindole selectivity.

Li X, Varga EV, Stropova D, Zalewska T, Malatynska E, Knapp RJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1996 Apr 4;300(1-2):R1-2.

PMID:
8741185

Supplemental Content

Loading ...
Support Center